Published in Int J Radiat Oncol Biol Phys on January 01, 2010
The impact of reduced-volume, intensity-modulated radiation therapy on disease control in nasopharyngeal carcinoma. PLoS One (2015) 0.80
DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer. BMC Cancer (2016) 0.78
Primary tumor volume delineation in head and neck cancer: missing the tip of the iceberg? Radiat Oncol (2017) 0.75
Dosimetric impact of target definitions on normal structures in head and neck cancer. Head Neck Oncol (2011) 0.75
Recurrent oropharyngeal cancer after organ preserving treatment: pattern of failure and survival. Eur Arch Otorhinolaryngol (2016) 0.75
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol (2009) 8.46
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol (2014) 5.80
Comparison of plan quality and delivery time between volumetric arc therapy (RapidArc) and Gamma Knife radiosurgery for multiple cranial metastases. Neurosurgery (2014) 3.38
Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol (2010) 2.71
Patterns of surgical care of lung cancer patients. Ann Thorac Surg (2005) 2.51
The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol (2003) 2.32
Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol (2012) 2.15
Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol (2007) 1.87
Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 1.81
Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison. J Nucl Med (2004) 1.81
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol (2007) 1.66
Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol (2010) 1.63
MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med (2010) 1.61
Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys (2008) 1.56
Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2002) 1.55
Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys (2009) 1.34
Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys (2002) 1.28
Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest (2006) 1.27
Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys (2008) 1.27
MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy. J Nucl Med (2008) 1.25
Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy. J Pain Symptom Manage (2009) 1.25
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood (2004) 1.24
The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy. Radiother Oncol (2011) 1.18
Prophylactic percutaneous endoscopic gastrostomy tube placement in treatment of head and neck cancer: a comprehensive review and call for evidence-based medicine. JPEN J Parenter Enteral Nutr (2011) 1.16
Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol (2008) 1.14
A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res (2002) 1.14
166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy. J Nucl Med (2006) 1.14
Mucosal melanoma: a clinically and biologically unique disease entity. J Natl Compr Canc Netw (2012) 1.14
Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53). J Clin Oncol (2007) 1.13
Postoperative radiotherapy in non-small-cell lung cancer warrants further exploration in the era of adjuvant chemotherapy and conformal radiotherapy. J Clin Oncol (2006) 1.13
Smoking behavior of 226 patients with diagnosis of stage IIIA/IIIB non-small cell lung cancer. Psychooncology (2002) 1.11
Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone. Int J Radiat Oncol Biol Phys (2007) 1.10
Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03. Am J Clin Oncol (2007) 1.08
Effects of bladder distension on organs at risk in 3D image-based planning of intracavitary brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys (2009) 1.06
Renal dosimetry. Cancer Biother Radiopharm (2010) 1.06
Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer (2002) 1.05
Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer. PLoS One (2011) 1.03
Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base. Clin Lung Cancer (2005) 1.01
Design and development of water-soluble curcumin conjugates as potential anticancer agents. J Med Chem (2007) 1.01
Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J Nucl Med (2005) 1.00
RapidArc radiation therapy: first year experience at the University of Alabama at Birmingham. Int J Radiat Oncol Biol Phys (2010) 0.96
HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair. Cancer Res (2012) 0.95
MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan. J Nucl Med (2009) 0.95
Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study. Anticancer Drugs (2006) 0.95
Targeted radionuclide therapy. Med Phys (2008) 0.95
Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin Cancer Res (2004) 0.94
Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a radiation therapy oncology group analysis. Int J Radiat Oncol Biol Phys (2007) 0.94
MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma. Clin Cancer Res (2012) 0.93
Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer (2005) 0.92
Small-cell lung cancer: prognostic factors and changing treatment over 15 years. Clin Lung Cancer (2011) 0.92
Flattening filter-free linac improves treatment delivery efficiency in stereotactic body radiation therapy. J Appl Clin Med Phys (2013) 0.92
Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors. Front Mol Neurosci (2011) 0.91
A dynamic supraclavicular field-matching technique for head-and-neck cancer patients treated with IMRT. Int J Radiat Oncol Biol Phys (2004) 0.91
Gastrostomy tube placement and use in patients with head and neck cancer. Head Neck (2011) 0.90
Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bioconjug Chem (2003) 0.90
MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy. J Nucl Med (2015) 0.89
Kinomic profiling approach identifies Trk as a novel radiation modulator. Radiother Oncol (2012) 0.89
Validation of target volume and position in respiratory gated CT planning and treatment. Med Phys (2003) 0.89
Quality of life in 650 lung cancer survivors 6 months to 4 years after diagnosis. Mayo Clin Proc (2004) 0.88
More on severe cutaneous reaction with radiotherapy and cetuximab. N Engl J Med (2007) 0.88
MIRD pamphlet No. 24: Guidelines for quantitative 131I SPECT in dosimetry applications. J Nucl Med (2013) 0.86
Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody. J Surg Res (2003) 0.86
Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer. Clin Breast Cancer (2010) 0.86
Comparison of methods to reduce dose to swallowing-related structures in head and neck cancer. Int J Radiat Oncol Biol Phys (2009) 0.85
Pulmonary resection after high-dose and low-dose chest irradiation. Ann Thorac Surg (2005) 0.84
Simultaneous optimization of sequential IMRT plans. Med Phys (2005) 0.83
Model prediction of treatment planning for dose-fractionated radioimmunotherapy. Cancer (2002) 0.83
Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy. J Med Chem (2010) 0.83
Role of radiation therapy and radiosurgery in glioblastoma multiforme. Cancer J (2003) 0.83
Prognostic significance of thyroid or cricoid cartilage invasion in laryngeal or hypopharyngeal cancer treated with organ preserving strategies. Radiat Oncol (2012) 0.83
Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein. Cancer Biother Radiopharm (2005) 0.82
Intraoperative radiotherapy for head and neck and skull base cancer. Head Neck (2003) 0.82
Influenza immunization in older adults with and without cancer. J Am Geriatr Soc (2012) 0.82
A new graphic for quality adjusted life years (Q-TWiST) survival analysis: the Q-TWiST plot. Qual Life Res (2002) 0.82
Diagnosis-to-treatment interval and control of locoregionally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg (2011) 0.81
Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy. J Nucl Med (2002) 0.81
Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer--RTOG 97-09. Int J Radiat Oncol Biol Phys (2003) 0.81
Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration. Cancer Biother Radiopharm (2005) 0.81
Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trial. Lung Cancer (2002) 0.81
Stage-specific survival differences associated with postoperative radiotherapy for gastrointestinal cancers. J Gastrointest Cancer (2009) 0.81
Stereotactic body radiation therapy (SBRT) for lung malignancies: preliminary toxicity results using a flattening filter-free linear accelerator operating at 2400 monitor units per minute. Radiat Oncol (2013) 0.80
Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma. J Nucl Med (2009) 0.80
Impact of average weekly dose of radiation during radiotherapy alone or chemoradiotherapy in head and neck cancer. Head Neck (2010) 0.80
Microvessel density >or=60 does not predict for outcome after radiation treatment for locally advanced head and neck squamous cell carcinoma: results of a correlative study from the Radiation Therapy Oncology Group (RTOG) 90-03 Trial. Am J Clin Oncol (2007) 0.79